Merck Launches Bio-Based HPLC Solvent Portfolio

Merck launches bio-based laboratory solvents for pharmaceutical testing

Merck Group has introduced a portfolio of bio-based solvents designed specifically for high-performance liquid chromatography (HPLC). The products are marketed under the LiChrosolv brand and include acetonitrile, methanol, and ethanol derived from renewable feedstocks. These materials deliver the same analytical performance as conventional petroleum-based solvents while reducing carbon dioxide equivalent emissions by an average of 25.9%.

For pharmaceutical manufacturers, environmental testing labs, and life sciences research facilities across the UK, this represents a practical route to lowering Scope 3 emissions without the cost and regulatory burden of method revalidation. The solvents work as direct replacements in existing HPLC and liquid chromatography-mass spectrometry systems. Laboratories can adopt them immediately.

Consequently, businesses facing pressure to demonstrate emissions reductions in supply chains or tender submissions now have a viable option. The products address a long-standing challenge: how to cut laboratory carbon footprints without compromising the precision required for regulated testing environments.

Bio-based content verified through international standards

The LiChrosolv bio-based solvents carry ASTM D6866 certification. This standard verifies the proportion of renewable carbon in a product using radiocarbon analysis. Specifically, the test measures carbon-14 isotopes, which are present in recently grown biomass but absent in fossil fuels.

Merck produces the solvents from renewable feedstocks rather than petroleum derivatives. However, the company has not disclosed specific sourcing details or the agricultural origins of the raw materials. The products undergo the same purification processes as conventional HPLC-grade solvents, maintaining the purity levels required for analytical work.

According to Merck’s published data, the bio-based portfolio achieves a 26% reduction in carbon dioxide equivalent emissions compared to traditional solvent production. This figure accounts for the full production cycle, including feedstock cultivation, processing, and distribution. Nevertheless, the calculation methodology and system boundaries have not been published in peer-reviewed literature.

The certification provides third-party verification of renewable content. This matters for businesses preparing carbon footprint reports or responding to customer due diligence requests. Documented bio-based content allows procurement teams to quantify emissions reductions when reporting Scope 3 purchased goods and services.

Drop-in compatibility eliminates method revalidation costs

The solvents are chemically identical to their petroleum-based equivalents. Therefore, they deliver the same chromatographic resolution, reproducibility, and baseline stability in analytical methods. Laboratories can substitute bio-based acetonitrile, methanol, or ethanol without adjusting instrument parameters, gradient profiles, or separation conditions.

This compatibility is particularly significant in Good Manufacturing Practice environments. Under GMP regulations, analytical methods used for batch release testing, stability studies, or impurity profiling must be validated to demonstrate accuracy, precision, and specificity. Any change to a method component typically triggers revalidation work. This involves repeat testing, documentation, and regulatory review, often costing tens of thousands of pounds and delaying production schedules.

By maintaining identical performance characteristics, Merck’s bio-based solvents avoid this burden. Quality control laboratories in pharmaceutical manufacturing can switch solvents without revalidating methods. Similarly, contract testing laboratories and research facilities can reduce emissions while maintaining continuity in their analytical workflows. Karen Madden, Chief Technology Officer of Merck’s Life Science business, stated that customers want solutions reducing environmental impact without compromising performance quality.

For UK manufacturers supplying the NHS or responding to public sector tenders, this matters. Procurement Policy Note 06/21 requires suppliers bidding for contracts above £5 million to publish carbon reduction plans. Switching to bio-based laboratory consumables provides documented evidence of emissions reduction efforts without operational disruption.

Applications span pharmaceutical development and quality control

HPLC is a fundamental analytical technique across pharmaceutical, biotechnology, and chemical sectors. The method separates, identifies, and quantifies compounds in complex mixtures. Solvents act as the mobile phase, carrying samples through chromatography columns where different components separate based on their chemical properties.

Merck’s bio-based solvents support multiple applications. In drug development, researchers use HPLC to characterise active pharmaceutical ingredients, assess purity, and identify degradation products. Manufacturing quality control teams rely on the technique for routine batch testing, ensuring each production run meets specification. Environmental testing laboratories use HPLC to detect contaminants in water, soil, and air samples. Diagnostic facilities employ the method to measure drug levels in patient samples.

The LiChrosolv portfolio targets high-volume solvent users. A typical pharmaceutical quality control laboratory may consume hundreds of litres of HPLC-grade acetonitrile annually. Similarly, contract research organisations conducting method development work use substantial quantities of methanol and ethanol. These facilities represent the core market for bio-based alternatives.

Each application demands consistent solvent performance. Variability in purity, water content, or UV absorbance can compromise analytical results. Consequently, laboratories often resist switching suppliers or product lines. Merck’s approach addresses this conservatism by ensuring the bio-based range performs identically to established products.

Carbon reduction verified across the production lifecycle

The 25.9% emissions reduction figure comes from lifecycle assessment comparing bio-based and petroleum-based solvent production. This analysis includes feedstock production, chemical processing, packaging, and distribution. However, Merck has not published the full assessment methodology or disclosed whether the comparison accounts for land use change associated with feedstock cultivation.

For businesses calculating Scope 3 emissions, the reduction translates directly to purchased goods and services. A laboratory using 500 litres of acetonitrile annually would reduce associated emissions by roughly 26% by switching to the bio-based equivalent. Over time, these reductions contribute to overall corporate carbon footprints reported under the Streamlined Energy and Carbon Reporting regulations.

The environmental benefit depends partly on feedstock sourcing. Renewable materials from sustainable agriculture deliver greater emissions reductions than those from land cleared specifically for biomass production. Additionally, transportation distances affect the overall carbon footprint. Solvents produced closer to end users generate lower distribution emissions.

UK businesses should request product-specific environmental data when evaluating bio-based solvents. Detailed information on feedstock origins, processing locations, and transportation routes allows more accurate emissions accounting. Furthermore, understanding the system boundaries of lifecycle assessments helps compare products from different suppliers.

Essential details for procurement and compliance teams

Several factors matter when considering bio-based laboratory solvents for procurement strategies. First, the products carry the same analytical performance specifications as conventional alternatives. Therefore, they suit both routine testing and regulated applications without method changes. Second, ASTM D6866 certification provides documented verification of renewable content, supporting carbon reporting requirements. Third, the approximate 26% emissions reduction applies specifically to solvent production and may vary based on supply chain configuration.

Businesses subject to SECR reporting should document the switch to bio-based consumables as part of their carbon reduction narrative. The change demonstrates tangible action beyond energy efficiency improvements. Moreover, organisations responding to PPN 06/21 requirements can cite the adoption of lower-carbon laboratory consumables in their carbon reduction plans.

Pricing information has not been publicly disclosed. Historically, bio-based chemical products have carried price premiums reflecting feedstock costs and smaller production volumes. However, as manufacturing scales increase, price gaps typically narrow. Procurement teams should request quotes comparing total cost of ownership, including any disposal cost differences for bio-based versus petroleum-based waste solvents.

Regulatory status remains unchanged. The bio-based solvents meet the same purity standards as conventional HPLC-grade materials. Consequently, they are suitable for use in validated analytical methods without additional regulatory submissions. Quality control laboratories can implement the switch through standard change control procedures rather than formal method revalidation.

Considerations for laboratories evaluating the switch

Laboratories should start with small-scale trials before committing to full adoption. Although Merck states the solvents perform identically to conventional options, internal verification provides confidence. Testing the bio-based acetonitrile on representative sample types confirms compatibility with existing methods and instruments.

Documentation matters for regulated environments. Laboratories should maintain records of the switch, including certificates of analysis for bio-based solvents, ASTM D6866 certification, and any internal testing results. This documentation supports audits and demonstrates due diligence in maintaining analytical quality while reducing environmental impact.

Supply chain continuity requires assessment. Businesses should confirm availability of bio-based solvents in required volumes and delivery timeframes. Additionally, understanding whether the supplier maintains buffer stock helps mitigate supply interruption risks. For critical applications, maintaining a parallel supply of conventional solvents during the transition phase provides backup options.

Waste disposal procedures may need review. Some solvent recycling services differentiate between petroleum-based and bio-based materials. Consequently, facilities should confirm with waste contractors whether bio-based solvents require different handling. In most cases, the chemical properties remain identical, so disposal procedures stay unchanged.

Training needs are minimal. Because the bio-based solvents work identically to conventional products, laboratory staff do not require extensive retraining. A brief communication explaining the switch and confirming that procedures remain unchanged typically suffices. However, purchasing and inventory teams should update procurement systems to reflect the new product specifications.

How this fits broader sustainability requirements for UK businesses

The availability of bio-based laboratory solvents reflects growing pressure on businesses to address Scope 3 emissions. These indirect emissions from purchased goods and services often represent the largest component of corporate carbon footprints. For pharmaceutical manufacturers and testing laboratories, consumables like solvents contribute materially to annual emissions totals.

Recent regulatory developments have intensified focus on supply chain emissions. The introduction of PPN 06/21 made carbon reduction plans mandatory for large public sector contracts. Similarly, the UK Hydrogen Strategy and related industrial decarbonisation policies signal government expectations for emission reductions across all sectors.

Our net-zero program for carbon reporting compliance helps businesses identify and quantify Scope 3 emissions from purchased goods and services. Many organisations discover that laboratory consumables represent a material emissions source once they complete detailed supply chain mapping. Switching to lower-carbon alternatives like bio-based solvents provides measurable reductions that strengthen carbon reduction plans.

Beyond compliance, sustainability performance increasingly affects commercial relationships. Large pharmaceutical companies and contract research organisations face questions from investors and customers about environmental practices. Demonstrating concrete actions, such as adopting bio-based consumables, helps respond to these inquiries with evidence rather than commitments alone.

The move toward bio-based materials also aligns with circular economy principles gaining traction across UK policy. Although solvents are typically incinerated after use rather than recycled, shifting to renewable feedstocks reduces reliance on finite petroleum resources. This transition mirrors broader industrial efforts to decarbonise chemical supply chains.

Further information on laboratory sustainability and carbon reporting

The Department for Energy Security and Net Zero publishes guidance on industrial decarbonisation and carbon reporting requirements. Additionally, the Greening Government Commitments framework outlines sustainability expectations for public sector organisations and their suppliers.

For businesses subject to mandatory carbon reporting, the Environmental Reporting Guidelines provide detailed methodology for calculating Scope 1, 2, and 3 emissions. The Companies Act 2006 (Strategic Report and Directors’ Report) Regulations 2013 establish the legal basis for SECR reporting.

Industry bodies such as the Institute of Environmental Management and Assessment offer technical guidance on lifecycle assessment methodologies and carbon accounting standards. These resources help businesses evaluate environmental claims and compare alternative products objectively.

Merck’s announcement of bio-based HPLC solvents arrives as UK laboratories face mounting pressure to reduce environmental impacts while maintaining analytical quality. The products offer a practical route to lowering Scope 3 emissions without operational disruption or method revalidation costs. For pharmaceutical manufacturers, contract testing laboratories, and research facilities, this represents a tangible step toward decarbonisation that aligns with regulatory expectations and customer requirements.